PKU microtablet case studies
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study is testing whether a new microtablet form of protein substitute is easy and acceptable for people with PKU to take. If you qualify, you'll take these tablets instead of your current protein substitute and share your experience with the research team.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 4 years old and have been diagnosed with PKU (a condition that causes high phenylalanine levels in the blood).
- You have been taking a protein substitute (a special formula) that gives you at least 20 grams of protein equivalent every day for the past month.
- You have been prescribed a daily phenylalanine limit by your doctor.
- You are not pregnant, not breastfeeding, and do not require IV nutrition.
- You do not have serious liver or kidney problems, and you have no allergies to the study product ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication taken as a pill to see if it can help people with PKU manage their condition. The study will check if the pill is safe and how it affects blood phenylalanine levels.
This study tests a new one-time gene therapy injection (called GS1168) for adults with phenylketonuria (PKU). It aims to help your body break down the amino acid phenylalanine better, so your diet may become less strict.
This study tests a new injection called PL54 to see if it is safe and tolerable for adults with phenylketonuria (PKU), a condition where the body cannot break down an amino acid called phenylalanine. It is designed for people with high blood phenylalanine levels and may offer a new treatment option.
This study looks at whether checking phenylalanine levels at home more often helps people with classic PKU keep their levels in a healthy range. It may help you manage your diet and treatment more effectively.
This study tests a new medicine called JNT-517 for people with phenylketonuria (PKU) over a long period. It aims to see if the drug can help manage PKU safely and effectively.
This trial is testing a new slow-release protein substitute for people with PKU, to see if it is acceptable and well-tolerated. You would try the product for 7 days, replacing your usual substitute, to see how it fits into your routine.
Hear when a new Phenylketonuria (PKU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.